1. Leos-Toro, C., Rynard, V., Hammond, D. Prevalence of problematic cannabis use in Canada: cross-sectional findings from the 2013 Canadian tobacco, alcohol and drugs survey. Can J Public Health. 2017;108(5-6):e516-e522.doi:10.17269/CJPH.108.5955
Google Scholar | Crossref2. Lowry, DE., Corsi, DJ. Trends and correlates of cannabis use in Canada: a repeated cross-sectional analysis of national surveys from 2004 to 2017. CMAJ Open. 2020;8(3):E487-E495.doi:10.9778/cmajo.20190229 32737023
Google Scholar | Crossref | Medline3. Imtiaz, S., Wells, S., Rehm, J et al. Cannabis use during the COVID-19 pandemic in Canada: a repeated cross-sectional study. J Addict Med. 2020.doi:10.1097/ADM.0000000000000798 33323693
Google Scholar | Medline4. Lim, M., Kirchhof, MG. Dermatology-related uses of medical cannabis promoted by dispensaries in Canada, Europe, and the United States. J Cutan Med Surg. 2019;23(2):178-184.doi:10.1177/1203475418808761 30380925
Google Scholar | SAGE Journals | ISI5. Canada, H . Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids: Dried Plant for Administration by Ingestion or Other Means. Health Canada, Ottawa, Canada. Published 2018. . https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html#a2.2.1.6
Google Scholar6. Ständer, S., Schmelz, M., Metze, D., Luger, T., Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38(3):177-188.doi:10.1016/j.jdermsci.2005.01.007 15927811
Google Scholar | Crossref | Medline7. Dhadwal, G., Kirchhof, MG. The risks and benefits of cannabis in the dermatology clinic. J Cutan Med Surg. 2018;22(2):194-199.doi:10.1177/1203475417738971 29056081
Google Scholar | SAGE Journals | ISI8. Baswan, SM., Klosner, AE., Glynn, K et al. Therapeutic potential of cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig Dermatol. 2020;13:927-942.doi:10.2147/CCID.S286411 33335413
Google Scholar | Crossref | Medline9. Watson, ES., Murphy, JC., Turner, CE. Allergenic properties of naturally occurring cannabinoids. J Pharm Sci. 1983;72(8):954-955.doi:10.1002/jps.2600720831 6620158
Google Scholar | Crossref | Medline10. Williams, C., Thompstone, J., Wilkinson, M. Work-related contact urticaria to cannabis sativa. Contact Dermatitis. 2008;58(1):62-63.doi:10.1111/j.1600-0536.2007.01169.x 18154568
Google Scholar | Crossref | Medline11. The World’s Most Popular Free Online Survey Tool . Survey Monkey. . https://www.surveymonkey.com/
Google Scholar12. Monkey, S . How to Collect Survey Responses Survey Monkey. . https://www.surveymonkey.com/mp/tour/responsecollection/
Google Scholar13. Chelliah, MP., Zinn, Z., Khuu, P., Teng, JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224-e227.doi:10.1111/pde.13545 29786144
Google Scholar | Crossref | Medline14. Schräder, NHB., Duipmans, JC., Molenbuur, B., Wolff, AP., Jonkman, MF. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Br J Dermatol. 2019;180(4):922-924.doi:10.1111/bjd.17341 30347109
Google Scholar | Crossref | Medline15. Lesort, C., Villani, AP., Giai, J et al. High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey. Br J Dermatol. 2019;181(4):839-841.doi:10.1111/bjd.17930 30920653
Google Scholar | Crossref | Medline16. Fernandez, JM., Thompson, AM., Borgstrom, M., Orenstein, LAV., Hsiao, JL., Shi, VY. Pain management modalities for hidradenitis suppurativa: a patient survey. J Dermatolog Treat. 2020:1-4.doi:10.1080/09546634.2020.1822501 32914659
Google Scholar | Medline17. Ständer, S., Reinhardt, HW., Luger, TA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt. 2006;57(9):801-807.doi:10.1007/s00105-006-1180-1 16874533
Google Scholar | Medline18. Pulvirenti, N., Nasca, MR., Micali, G. Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerol Croat. 2007;15(2):80-83.
Google Scholar | Medline19. Yuan, C., Wang, X-M., Guichard, A et al. N-Palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. Clin Interv Aging. 2014;9:1163-1169.doi:10.2147/CIA.S65448 25071367
Google Scholar | Crossref | Medline20. Visse, K., Blome, C., Phan, NQ., Augustin, M., Ständer, S. Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: a Dermatocosmetic study. Acta Derm Venereol. 2017;97(5):639-641.doi:10.2340/00015555-2593 27983740
Google Scholar | Crossref | Medline21. Lo Verme, J., Fu, J., Astarita, G et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19.doi:10.1124/mol.104.006353 15465922
Google Scholar | Crossref | Medline | ISI22. Eberlein, B., Eicke, C., Reinhardt, H-W., Ring, J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study. J Eur Acad Dermatol Venereol. 2008;22(1):73-82.doi:10.1111/j.1468-3083.2007.02351.x 18181976
Google Scholar | Medline23. Sikorski, C., Leos-Toro, C., Hammond, D. Cannabis consumption, purchasing and sources among young Canadians: the cannabis purchase and consumption tool (CPCT). Subst Use Misuse. 2021;56(4):449-457.doi:10.1080/10826084.2021.1879142 33593238
Google Scholar | Crossref | Medline24. Capler, R., Walsh, Z., Crosby, K et al. Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. Int J Drug Policy. 2017;47(10):1-8.doi:10.1016/j.drugpo.2017.05.046 28667878
Google Scholar | Crossref | Medline25. Adler, BL., DeLeo, VA. Allergenic ingredients in commercial topical cannabinoid preparations. J Am Acad Dermatol. 2019;81(3):847-848.doi:10.1016/j.jaad.2019.03.015 30885758
Google Scholar | Crossref | Medline26. Yin, HY., Hadjokas, N., Mirchia, K., Swan, R., Alpert, S. Commercial cannabinoid oil-induced Stevens-Johnson syndrome. Case Rep Ophthalmol Med. 2020;2020:1-5.doi:10.1155/2020/6760272 32148986
Google Scholar | Crossref | Medline27. Huestis, MA . Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804.doi:10.1002/cbdv.200790152 17712819
Google Scholar | Crossref | Medline28. Casiraghi, A., Musazzi, UM., Centin, G., Franzè, S., Minghetti, P. Topical administration of cannabidiol: influence of vehicle-related aspects on skin permeation process. Pharmaceuticals. 2020;13(11):337.doi:10.3390/ph13110337 33114270
Google Scholar | Crossref | Medline29. Government of Canada . Understanding the New Access to Cannabis for Medicinal Purposes Regulations [Web page]. Ottawa, ON: Health Caada;2016 ]. . https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html;
Google Scholar30. Yeroushalmi, S., Nelson, K., Sparks, A., Friedman, A. Perceptions and recommendation behaviors of dermatologists for medical cannabis: a pilot survey. Complement Ther Med. 2020;55(11):102552. doi:10.1016/j.ctim.2020.102552 33220620
Google Scholar | Crossref | Medline31. Kruger, DJ., Kruger, JS., Collins, RL. Cannabis Enthusiasts’ Knowledge of Medical Treatment Effectiveness and Increased Risks From Cannabis Use. Am J Health Promot. 2020;34(4):436-439.doi:10.1177/0890117119899218
Google Scholar | SAGE Journals | ISI32. Yeung, M., Wroot, H., Charnock, C., Forbes, C., Lafay-Cousin, L., Schulte, F. Cannabis use in pediatric cancer patients: what are they reading? A review of the online literature. Support Care Cancer. 2020;28(8):3503-3515.doi:10.1007/s00520-020-05306-2 31960125
Google Scholar | Crossref | Medline